Clinicians and drug developers urgently need non-invasive biomarkers for non-alcoholic steatohepatitis (NASH). NASH is the most common cause of liver disease in the West and is expected to be the first cause for liver transplantation in a few years making it critical to identify high-risk patients early. But liver biopsy-the gold standard for diagnosis-has limited use as a screening tool and as a surrogate endpoint. Additionally, there is a need for non-invasive methods that can achieve reliable results in short time frames in proof of concept trials. To achieve reliable results in shorter time frames, drug developers must ultimately adopt new non-invasive testing strategies.
In this webinar, our subject matter experts will bring you up-to-date on the latest advances in non-invasive biomarkers for NASH. We'll discuss the limitations of liver biopsies, such as inter-subject variability and lack of representative pathology results. The reliability of available biomarkers and composite test panels will be reviewed, as well as techniques for leveraging genomics in NASH. Finally, we'll explore potential applications in clinical assessment and drug development.
Join us for a wide-ranging discussion on:
- The urgent need for non-invasive biomarkers in NASH
- Insights into non-invasive diagnosis of NASH and liver fibrosis: present and future
- Leveraging genomics in NASH
- Strategic use of non-invasive tests in NASH drug development
- The role of non-invasive biomarkers in clinical practice
Advances in non-invasive biomarkers are the key to accelerated NASH development. To learn more about the rapid changes in this field, register for this webinar.
Claudia Filozof, MD, PhD,
Senior Medical Director, Cardiovascular/Metabolic, Covance
Dr. Filozof is responsible for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis projects at Covance. Dr. Filozof is board certified in nutrition and metabolism, has more than 20 years of experience in academia and has more than 10 years of service in the pharmaceutical industry. She has broad expertise in diabetes, obesity and related metabolic disorders including non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH).
Margery A. Connelly, PhD, MBA,
Vice President, Translational Research, LabCorp (LipoScience)
Dr. Connelly has over 20 years of experience in academia and the pharmaceutical industry. She has spent the last 3 years applying her scientific expertise toward the development and clinical validation of new NMR-based biomarkers for various disease indications, including cardiovascular disease, inflammation and metabolic disorders such as metabolic syndrome, diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Mark L. Parrish, BS,
Associate Scientific Director of Genomic Solutions, Covance
Parrish has more than 15 years of experience dedicated to the development of high-throughput, high-quality genomics tools for drug development. He has cultivated a diverse publication record, having published in the areas of plant sciences, molecular biology, genomics and medicine. He has a broad knowledge of numerous platforms and technologies for gene expression, genotyping and microRNA profiling. Parrish was a founding scientist of the Rosetta Inpharmatics Gene Expression Laboratory, the industry-leading provider of genomics services, later acquired by Merck and Covance, which now provides a full breadth of Covance and LabCorp genomics capabilities.
Arun Sanyal, MD,
Executive Director, Education Core, Center for Clinical and Translational Research
Dr. Sanyal has 20 years of experience as an academic hepatologist and as a trainer of future generations of clinician and investigators. His research program has spanned both basic and clinical aspects of end-stage liver disease and non-alcoholic fatty liver disease and has led to recommendations related to variceal hemorrhage, ascites, hepatorenal syndrome, hepatic encephalopathy and nonalcoholic steatohepatitis in the relevant practice guidelines of various national societies.
- Understand the limitations of liver biopsy as a NASH screening tool
- Hear about the reliability of available biomarkers and composite test panels
- Learn how to leverage genomics in NASH development
- Find out about the use of non-invasive biomarkers in clinical practice and drug development
- Clinical Development Manager
- Clinical Developer
- Pharmaceutical Development Manager
- Contract Manufacturing Manager
- External Outsourcing Manager
- Head of R&D
- Lead Scientist
